CClinicalTrials.gg
Sign In
Status unknownNCT05290077Updated Oct 31, 2022

Role of NGAL in Vitiligo

An interventional study of NGAL in Vitiligo, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-31.

Sponsored by Sohag University · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo

02

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • NGAL & CVR
03

In context

Vitiligo

298 studies on the registry are indexed under Vitiligo; 69 are open to participants now.

This study's planned enrollment of 90 is above the median of 30 across 227 interventional studies indexed under Vitiligo.

Browse Vitiligo studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • patients with vitiligo above 20y

Exclusion criteria

Exclusion Criteria:

  • patients with systemic disease Pregnants female Lactating females Patients less than 20 y Patients with active lesions
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Cases

    group of vitiligo patients

    Diagnostic Test: NGAL

  • Active comparator
    control group

    healthy group

    Diagnostic Test: NGAL

Interventions

  • Diagnostic testNGAL

    Serum NGAL in blood for early detection of CVR

06

What researchers measure

Primary outcomes

  1. serum Neutrophil Gelatinase-associated Lipocalin in patients with Vitilig

    Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo

    Time frame: 6 months

07

Study locations

1 site
  • Sohag fuculty
    Sohag, Egypt
08

References and documents

Publications

  • Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. PubMed 25596811 ↗
  • Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance. Biomed Res Int. 2017;2017:5617838. doi: 10.1155/2017/5617838. Epub 2017 Jul 30. PubMed 28828385 ↗
  • Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb;149(2):159-64. doi: 10.1001/jamadermatol.2013.927. PubMed 23560296 ↗
  • Mazzei Weiss ME. Vitiligo: to biopsy or not to biopsy? Cutis. 2020 Apr;105(4):189-190. No abstract available. PubMed 32463851 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05290077
Lead sponsor
Sohag University
Responsible party
Doaa Gamal Hafez (resident doctor at dermatology department sohag university hospital, Sohag University) — Principal investigator
First posted
Mar 22, 2022
Start date
Dec 15, 2022 (estimated)
Primary completion
Dec 15, 2022 (estimated)
Completion
Dec 15, 2022 (estimated)
Last update
Oct 31, 2022

Study contacts

Doaa G Hafez, resident
Contact
Doaag63@yahoo.com
01062472611
Marwa M Abd El-Meged, professor
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Vitiligo→

Other studies from this sponsor

Sohag University

Start the discussion